Vanillactate
Vanillactate is an organic acid, specifically a derivative of vanillin, which is widely recognized for its characteristic aroma and flavor. As a hydroxylated phenylacetic acid, vanillactate features a vanillyl group and a lactic acid moiety. Its chemical structure is 2-hydroxy-3-(4-hydroxy-3-methoxyphenyl)propanoic acid.
Biological Basis
Section titled “Biological Basis”Vanillactate often arises as a metabolite in biological systems through the breakdown or modification of vanilla-related compounds. It can be formed from vanillin, a common component in human diet and the environment, through metabolic pathways involving enzymatic reduction and subsequent oxidation or hydration reactions. In the human body, the metabolism of aromatic compounds, including those derived from diet or produced by gut microbiota, can lead to the formation of such phenolic acids. These metabolic processes typically involve enzymes in the liver and kidneys, as well as microbial enzymes in the gut, which can convert precursors like vanillin into various metabolites, including vanillactate.
Clinical Relevance
Section titled “Clinical Relevance”The presence and concentration of vanillactate in biological fluids, such as urine or blood, can sometimes serve as a biomarker for certain metabolic states or exposures. For instance, it has been explored in the context of disorders affecting aromatic amino acid metabolism or in studies evaluating the impact of dietary components. Research often focuses on how altered levels of such metabolites might indicate changes in gut microbiota activity, dietary intake, or specific enzyme deficiencies related to detoxification or metabolic pathways. Vanillactate and similar phenolic acids are also studied for their potential antioxidant properties and their role in modulating cellular processes, which could have implications for chronic disease prevention.
Social Importance
Section titled “Social Importance”From a societal perspective, understanding metabolites like vanillactate contributes to broader research in several areas. In nutritional science, it aids in understanding the systemic impact of food additives and natural compounds found in diets, particularly those rich in vanilla or related phenolics. In environmental health, it contributes to knowledge about human exposure to and metabolism of a wide range of organic compounds. Furthermore, in clinical diagnostics, its potential as a biomarker supports the development of non-invasive tests for metabolic profiling, offering insights into health status and disease progression. Its presence also highlights the complex interplay between diet, gut microbiome, and human metabolism in overall health.
Limitations
Section titled “Limitations”Methodological and Statistical Considerations
Section titled “Methodological and Statistical Considerations”The current understanding of vanillactate levels is shaped by studies employing various methodologies, which inherently introduce limitations. Many investigations rely on imputation analyses based on reference panels like HapMap, such as build 35 or release 21/22[1], [2]. [3] While imputation facilitates broader genomic coverage and comparison across different genotyping platforms, it carries an inherent error rate, typically estimated between 1.46% and 2.14% per allele. [1] Furthermore, the selection of SNPs based on thresholds like an RSQR≥ 0.3 for meta-analysis or the use of only a subset of all known SNPs can result in incomplete coverage, potentially missing causal variants or genes that influence vanillactate levels but are not sufficiently represented[2]. [4]
Statistical challenges further impact the interpretation of findings. Initial genome-wide association (GWA) screens may report associations with larger effect sizes, underscoring the critical need for independent replication in distinct cohorts to confirm their validity and prevent effect-size inflation[5]. [6] Although meta-analyses, often using fixed-effects inverse-variance weighting, combine data from multiple studies to increase statistical power and identify additional genetic variants [2], [7]the collective sample sizes, though substantial (e.g., thousands of individuals [3], [7], [8]), may still be insufficient to detect all genetic influences. Moreover, study design choices, such as performing only sex-pooled analyses, risk overlooking sex-specific genetic associations that might be crucial for understanding vanillactate regulation.[4]
Generalizability and Phenotype Characterization
Section titled “Generalizability and Phenotype Characterization”A primary limitation of many studies is the restricted demographic composition of their cohorts, primarily comprising individuals of European or Caucasian ancestry [3], [7], [8], [9]. [10] While measures like principal component analysis and genomic control are applied to mitigate the effects of population stratification, this narrow ancestral focus means that the generalizability of findings to other ethnic groups, including diverse multiethnic populations, remains largely unexplored [3], [7], [8]. [9]This demographic bias significantly limits the universal applicability of the identified genetic associations for vanillactate levels.
The methods used for phenotype assessment also introduce limitations. For instance, some studies average physiological traits across multiple examinations conducted over extensive periods, potentially spanning decades, and often involve different equipment. [9] This approach can lead to misclassification and may mask age-dependent gene effects, as it assumes a consistent genetic and environmental influence over a wide age range. [9] Furthermore, the common practice of excluding participants taking specific medications (e.g., lipid-lowering therapies) or those with conditions like diabetes, while aiming for a more homogeneous study population, can limit the direct applicability of findings to the broader population, especially individuals under treatment or with co-morbidities [1]. [8]
Incomplete Understanding and Future Directions
Section titled “Incomplete Understanding and Future Directions”The current genetic studies primarily focus on identifying statistical associations between genetic loci and vanillactate levels, but a comprehensive understanding of the interplay between genetic predispositions and environmental factors remains largely underexplored. While it is implicitly recognized that environmental influences contribute to trait variability[9]the specific gene-environment interactions that modulate vanillactate levels are not extensively detailed in the provided research. This gap in knowledge means that aspects of “missing heritability” — the proportion of heritable variation not explained by identified genetic factors — may persist due to uncharacterized environmental or gene-environment confounders.
Ultimately, the statistical associations identified through genome-wide approaches necessitate further investigation. Functional validation studies are crucial to elucidate the precise biological mechanisms through which identified single nucleotide polymorphisms (SNPs) or genes influence vanillactate levels.[6] Genome-wide association studies (GWAS) often do not provide sufficient detail for a comprehensive understanding of candidate genes or to pinpoint the exact causal variants. [4]Therefore, ongoing research must prioritize functional characterization and replication in diverse cohorts to translate these genetic discoveries into a more complete biological understanding of vanillactate metabolism and its clinical implications.
Variants
Section titled “Variants”The genetic variants rs75659883 and rs113945618 are situated in regions containing genes critical for growth, development, and metabolic regulation. The rs75659883 variant is located within the imprinted H19-IGF2 locus, a well-studied genomic region involved in cellular growth and differentiation. H19 is a long non-coding RNA (lncRNA) that acts as a tumor suppressor and influences gene expression, while IGF2(Insulin-like Growth Factor 2) is a potent growth factor essential for fetal development and postnatal metabolism, particularly in regulating glucose and lipid levels. Variations in this region, such asrs75659883 , can impact the delicate balance of H19 and IGF2expression, potentially affecting metabolic processes. Research indicates that insulin-like growth factors and triglycerides are relevant to metabolic health, suggesting a broader role for this locus in such traits.[11] Indeed, many genetic studies have identified loci associated with lipid concentrations, including triglycerides, underscoring the importance of such variants in metabolic regulation. [1]
Further contributing to metabolic and developmental pathways, the rs113945618 variant is associated with MIR4686 and ASCL2. MIR4686 is a microRNA, a small non-coding RNA that fine-tunes gene expression by regulating messenger RNA (mRNA) stability and translation. Changes in microRNA activity, potentially influenced by variants like rs113945618 , can have widespread effects on cellular processes. ASCL2 (Achaete-scute homolog 2) is a transcription factor vital for cell fate determination and differentiation, especially in intestinal epithelial cells and placental development. As an imprinted gene, ASCL2 plays a crucial role in maintaining stem cell populations and driving tissue development. The impact of rs113945618 on MIR4686 or ASCL2could therefore affect fundamental developmental and homeostatic mechanisms. Such genetic variations are known to influence various metabolic traits, including glucose and insulin levels, highlighting their broad physiological relevance.[12]
Collectively, these variants represent key genetic determinants that can influence the body’s metabolic landscape, which includes intermediate metabolites like vanillactate. Vanillactate, a microbial metabolite, can reflect aspects of gut health or host-microbiome interactions, which in turn can be influenced by host genetics. Alterations in growth factor signaling viaIGF2 or developmental pathways orchestrated by ASCL2, potentially modulated by MIR4686, could indirectly impact the gut environment and overall metabolic homeostasis. For instance, associations between genetic variants in other genes likeSLC2A9 and metabolic parameters such as triglycerides and HDL cholesterol demonstrate the intricate genetic architecture underlying complex metabolic traits. [13] Understanding how rs75659883 and rs113945618 perturb these biological systems offers insight into their potential implications for a spectrum of health conditions and biochemical profiles, including levels of metabolites such as vanillactate.
Key Variants
Section titled “Key Variants”| RS ID | Gene | Related Traits |
|---|---|---|
| rs75659883 | H19 - IGF2 | vanillactate measurement |
| rs113945618 | MIR4686 - ASCL2 | serum metabolite level 3-methoxytyrosine measurement vanillactate measurement |
Biological Background
Section titled “Biological Background”Genetic Basis of Metabolic Regulation
Section titled “Genetic Basis of Metabolic Regulation”Genetic mechanisms play a fundamental role in governing the intricate networks of metabolic processes within the human body. Variations in an individual’s DNA, such as single nucleotide polymorphisms (SNPs), can significantly influence the function and expression of genes involved in key biochemical pathways.[12] These genetic variants can impact regulatory elements, affecting how genes are transcribed and translated into functional proteins, or they can alter the structure of the proteins themselves. [14] For instance, common SNPs can influence alternative splicing, a process where different protein isoforms are produced from a single gene, thereby modifying cellular functions and overall metabolic output. [14] Understanding these genetic underpinnings is crucial for elucidating the precise molecular and cellular mechanisms that dictate an individual’s metabolic profile.
Gene functions are often mediated by critical biomolecules such as enzymes, receptors, and transcription factors that form complex regulatory networks. For example, specific transcription factors like MLXIPLare known to be associated with plasma triglyceride levels, indicating their role in lipid metabolism and systemic homeostatic regulation.[15] Similarly, enzyme activity, like that of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), a key enzyme in cholesterol synthesis, can be modulated by genetic variations. [14] These genetic influences contribute to the observed variability in metabolic traits across populations, highlighting the profound impact of genetic makeup on fundamental biological processes.
Key Pathways in Lipid Homeostasis
Section titled “Key Pathways in Lipid Homeostasis”Lipid homeostasis is a complex biological process involving the synthesis, transport, and breakdown of various lipids, critical for cellular function and overall physiological health. Central to cholesterol synthesis is the mevalonate pathway, where the enzyme HMGCR catalyzes a rate-limiting step. [14] Genetic variants affecting HMGCRcan lead to altered activity of this enzyme, subsequently influencing low-density lipoprotein cholesterol (LDL-C) levels in the blood.[14]Dysregulation of LDL-C, alongside high-density lipoprotein cholesterol (HDL-C) and triglycerides, is a major pathophysiological process implicated in conditions such as coronary artery disease.[1]
Another crucial enzyme in lipid metabolism is lecithin:cholesterol acyltransferase (LCAT), which plays a vital role in the maturation of HDL particles and the reverse cholesterol transport pathway. Deficiencies in LCATlead to distinct syndromes characterized by severe disruptions in lipid concentrations and lipoprotein profiles, underscoring its importance in maintaining lipid balance.[16] Furthermore, gene variations influencing transcription factors like MLXIPLcan have systemic consequences by affecting triglyceride levels, demonstrating how specific genetic modifications can propagate through metabolic pathways to impact organ-level lipid regulation and overall cardiovascular health.[15]
Uric Acid Transport and Renal Excretion
Section titled “Uric Acid Transport and Renal Excretion”The maintenance of uric acid homeostasis is a tightly regulated process involving several key biomolecules, particularly transporters responsible for its excretion and reabsorption, predominantly in the kidneys. The solute carrier family 2 member 9,SLC2A9 (also known as GLUT9), has been identified as a significant urate transporter influencing serum urate concentrations and urate excretion.[17] Genetic variants within SLC2A9are associated with altered serum uric acid levels, and these effects can exhibit sex-specific differences, highlighting complex regulatory mechanisms at the tissue and organ level.[18]
Disruptions in uric acid homeostasis, often mediated by the function of transporters likeSLC2A9 or GLUT9, are directly linked to pathophysiological processes such as gout.[17]Certain common nonsynonymous variants, including valine to isoleucine substitutions, within genes likeGLUT9can lead to altered protein structure and function, thereby impacting its transport capabilities and contributing to changes in serum uric acid levels.[13]These genetic insights reveal critical regulatory networks controlling renal handling of urate and underscore the genetic predisposition to conditions arising from impaired uric acid balance.
Interplay of Genetics, Metabolomics, and Disease
Section titled “Interplay of Genetics, Metabolomics, and Disease”The rapidly evolving field of metabolomics, which involves the comprehensive measurement of endogenous metabolites in biological fluids, provides a functional readout of the physiological state of the human body and offers profound insights into pathophysiological processes. [12] When combined with genome-wide association studies (GWAS), metabolomics enables the identification of genetic variants that alter the homeostasis of key lipids, carbohydrates, or amino acids. [12]This approach moves beyond simply associating genotypes with clinical outcomes, allowing for a more detailed understanding of disease-causing mechanisms by linking genetic predispositions to specific intermediate metabolic phenotypes.[12]
Identifying genetically determined metabotypes is mandatory for a functional understanding of complex diseases, as the effect sizes of genetic associations with clinical phenotypes can often be small. [12]Such studies reveal how genetic variation in genes, like those involved in lipid or uric acid metabolism, can lead to systemic consequences and contribute to the etiology of complex diseases like coronary artery disease or gout.[1]By probing the human metabolic network in detail, the integration of genomics and metabolomics opens new avenues for investigating gene-environment interactions and developing individualized approaches to medication and disease management.[12]
Pathways and Mechanisms
Section titled “Pathways and Mechanisms”Metabolic Homeostasis and Energetic Flux
Section titled “Metabolic Homeostasis and Energetic Flux”The biological mechanisms underlying vanillactate are intricately linked to core metabolic pathways that maintain cellular and systemic homeostasis, encompassing lipid, urate, and glucose metabolism. Regulation of lipid levels is critical, as exemplified by the mevalonate pathway, whereHMGCR is a key enzyme controlling cholesterol biosynthesis. [19] This pathway is subject to sophisticated metabolic regulation and flux control to ensure appropriate energy substrate availability and membrane component synthesis. [19]Furthermore, the homeostasis of urate, a vital antioxidant and waste product, is managed through its synthesis and excretion pathways, with its circulating levels being a critical metabolic phenotype.[17]
Beyond lipids and urate, glucose metabolism also plays a fundamental role. Enzymes likeHK1(hexokinase 1) are involved in the initial steps of glucose phosphorylation, impacting overall glucose utilization and glycated hemoglobin levels.[8] Specific genes such as CDKAL1, IGF2BP2, CDKN2A/B, HHEX, SLC30A8, and KCNJ11are implicated in the susceptibility to type 2 diabetes, indicating their collective role in insulin secretion, sensitivity, and systemic glucose regulation.[20] These interconnected metabolic processes demonstrate how the body orchestrates energy production, storage, and waste management, which can profoundly influence complex physiological traits.
Molecular Transport and Systemic Balance
Section titled “Molecular Transport and Systemic Balance”Effective molecular transport mechanisms are essential for maintaining the systemic balance of various metabolites, directly impacting their availability and clearance. A prime example is the facilitative glucose transporterSLC2A9 (also known as GLUT9), which serves as a newly identified urate transporter.[17]This transporter is crucial for influencing serum urate concentration and urinary urate excretion, thus playing a direct role in urate homeostasis.[17]Its function in regulating circulating urate levels has significant implications, including pronounced sex-specific effects on uric acid concentrations.[18]
Beyond urate, specific zinc transporters, such asZnT-8 (SLC30A8), are vital for maintaining the balance of essential micronutrients and are functionally characterized in glucose-induced insulin secretion.[21] The cellular localization of ZnT-8within insulin secretory granules highlights its role in the regulated release of insulin, thereby influencing systemic glucose regulation.[22] These specialized transport proteins are pivotal in controlling metabolite flux across biological membranes, ensuring proper physiological function and impacting the overall biochemical profile.
Genetic and Post-Translational Regulatory Control
Section titled “Genetic and Post-Translational Regulatory Control”The pathways influencing vanillactate are subject to multiple layers of regulatory control, ranging from gene expression to post-translational modifications. Gene regulation plays a critical role, where common single nucleotide polymorphisms (SNPs) can impact the alternative splicing of genes, such as exon 13 ofHMGCR, thereby affecting LDL-cholesterol levels. [23] This mechanism demonstrates how genetic variation can alter protein structure and function, leading to changes in metabolic output. Transcriptional regulation is also key, with factors like SREBP-2 (Sterol Regulatory Element-Binding Protein 2) directly regulating genes involved in isoprenoid and adenosylcobalamin metabolism, thus linking sterol sensing to metabolic pathways. [24]
Protein modification, including alternative splicing, constitutes a significant form of post-translational regulation that enhances functional diversity from a limited set of genes. [25] Such precise control over gene expression and protein isoforms ensures adaptable cellular responses to varying metabolic demands. These regulatory mechanisms collectively orchestrate the dynamic control of protein abundance and activity, finely tuning metabolic pathways and influencing the overall physiological state that shapes complex traits.
Interconnected Signaling and Disease Pathogenesis
Section titled “Interconnected Signaling and Disease Pathogenesis”The intricate web of pathways relevant to vanillactate involves extensive crosstalk and network interactions at a systems level, which are crucial for integrated physiological responses and are often implicated in disease pathogenesis. Signaling cascades, such as those involving mitogen-activated protein kinases (MAPK), are regulated by protein families like Tribbles, which can mediate intracellular communication and modulate diverse cellular processes.[26] These cascades can be influenced by metabolic states and, in turn, regulate downstream gene expression or protein activity, forming complex feedback loops that maintain biological equilibrium.
Dysregulation within these integrated pathways can lead to various disease-relevant mechanisms, including pathway dysregulation that manifests as complex traits like dyslipidemia. Genetic variants influencing lipid concentrations, such as those inANGPTL3 and ANGPTL4, significantly contribute to polygenic dyslipidemia and increase the risk of coronary artery disease.[1]Similarly, the dysregulation of urate transport bySLC2A9can contribute to conditions like gout, highlighting its potential as a therapeutic target.[17] Understanding these network interactions and their hierarchical regulation provides insights into emergent properties of biological systems and identifies potential targets for therapeutic intervention in complex diseases.
References
Section titled “References”[1] Willer, C. J., et al. “Newly identified loci that influence lipid concentrations and risk of coronary artery disease.”Nat Genet, vol. 40, no. 2, 2008, pp. 161-169. PMID: 18193043.
[2] Yuan, X., et al. “Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes.” Am J Hum Genet, vol. 83, no. 5, 2008, pp. 520-528. PMID: 18940312.
[3] Dehghan, A. “Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study.”Lancet, 2008.
[4] Yang, Q., et al. “Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study.”BMC Med Genet, vol. 8, suppl. 1, 2007, p. S10. PMID: 17903294.
[5] Sabatti, C. “Genome-wide association analysis of metabolic traits in a birth cohort from a founder population.”Nat Genet, 2008.
[6] Benjamin, E. J., et al. “Genome-wide association with select biomarker traits in the Framingham Heart Study.” BMC Med Genet, vol. 8, suppl. 1, 2007, p. S9. PMID: 17903293.
[7] Kathiresan, S., et al. “Common variants at 30 loci contribute to polygenic dyslipidemia.” Nat Genet, vol. 41, no. 1, 2009, pp. 56-65. PMID: 19060906.
[8] Pare, G, et al. “Novel association of HK1with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women’s Genome Health Study.”PLoS Genet, vol. 4, no. 12, 2008, e1000322.
[9] Vasan, R. S., et al. “Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study.”BMC Med Genet, vol. 8, suppl. 1, 2007, p. S2. PMID: 17903301.
[10] Aulchenko, Y. S., et al. “Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts.”Nat Genet, vol. 41, no. 1, 2009, pp. 47-55. PMID: 19060911.
[11] Saxena, R, et al. “Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels.”Science, vol. 316, 2007, pp. 1331–1336.
[12] Gieger, C, et al. “Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum.”PLoS Genet, vol. 4, no. 11, 2008, e1000282.
[13] McArdle, Patrick F., et al. “Association of a Common Nonsynonymous Variant in GLUT9 with Serum Uric Acid Levels in Old Order Amish.”Arthritis Rheum, vol. 58, no. 12, Dec. 2008, pp. 3994-4001.
[14] Burkhardt, Rita, et al. “Common SNPs in HMGCR in Micronesians and Whites Associated with LDL-Cholesterol Levels Affect Alternative Splicing of Exon13.” Arterioscler Thromb Vasc Biol, vol. 29, no. 3, Mar. 2009, pp. 411-18.
[15] Kooner, Jaspal S., et al. “Genome-Wide Scan Identifies Variation in MLXIPL Associated with Plasma Triglycerides.” Nat Genet, vol. 40, no. 2, Feb. 2008, pp. 149-51.
[16] Kuivenhoven, Jan A., et al. “The Molecular Pathology of Lecithin:Cholesterol Acyltransferase (LCAT) Deficiency Syndromes.” J Lipid Res, vol. 38, no. 2, Feb. 1997, pp. 191-205.
[17] Vitart, V, et al. “SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout.”Nat Genet, vol. 40, no. 4, 2008, pp. 437–442.
[18] Doring, Angela, et al. “SLC2A9 Influences Uric Acid Concentrations with Pronounced Sex-Specific Effects.”Nat Genet, vol. 40, no. 4, Apr. 2008, pp. 430-36.
[19] Goldstein, JL, and MS Brown. “Regulation of the mevalonate pathway.” Nature, vol. 343, 1990, pp. 425–430.
[20] Omori, S, et al. “Association of CDKAL1, IGF2BP2, CDKN2A/B, HHEX, SLC30A8, and KCNJ11 with susceptibility to type 2 diabetes in a Japanese population.” Diabetes, vol. 57, 2008, pp. 791–795.
[21] Chimienti, F, et al. “In vivo expression and functional characterization of the zinc transporter ZnT8 in glucose-induced insulin secretion.”J Cell Sci, vol. 119, 2006, pp. 4199–4206.
[22] Chimienti, F, et al. “Identification and cloning of a beta-cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules.”Diabetes, vol. 53, 2004, pp. 2330–2337.
[23] Burkhardt, R, et al. “Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.” Arterioscler Thromb Vasc Biol, 2008.
[24] Murphy, C, et al. “Regulation by SREBP-2 defines a potential link between isoprenoid and adenosylcobalamin metabolism.” Biochem Biophys Res Commun, vol. 355, 2007, pp. 359–364.
[25] Johnson, JM, et al. “Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays.” Science, vol. 302, 2003, pp. 2141–2144.
[26] Kiss-Toth, E, et al. “Human tribbles, a protein family controlling mitogen-activated protein kinase cascades.” J Biol Chem, vol. 279, 2004, pp. 42703–42708.